Back to Search
Start Over
Novel targeted therapies in head and neck cancer.
- Source :
-
Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2012 Mar; Vol. 21 (3), pp. 281-95. Date of Electronic Publication: 2012 Jan 12. - Publication Year :
- 2012
-
Abstract
- Introduction: Molecularly targeted therapy, with the potential for increased selectivity and fewer adverse effects, hold promise in the treatment of HNSCC.<br />Areas Covered: Targeted agents for HNSCC expected to improve the effectiveness of current therapy including HER family, Src-family kinase, cell cycle, MET, AKT, HDAC, PARP, COX inhibitors and antiangiogenesis.<br />Expert Opinion: Epidermal growth factor receptor inhibitors are established in HNSCC and the need now is to find biomarkers for sensitivity to better select patients. Moreover, other pathway inhibitors hold significant promise and are being tested in clinical trials. Angiogenesis inhibition is likely to yield only modest efficacy alone but may augment existing standards. Lastly, one clinical arena where targeted therapies may find secure purchase is in the adjuvant or prevention setting where minimal or preneoplastic disease can be affected by inhibition of a single or few targets.
- Subjects :
- Angiogenesis Inhibitors adverse effects
Angiogenesis Inhibitors pharmacology
Angiogenesis Inhibitors therapeutic use
Animals
Antineoplastic Agents adverse effects
Antineoplastic Agents pharmacology
Carcinoma, Squamous Cell pathology
Head and Neck Neoplasms pathology
Humans
Molecular Targeted Therapy
Signal Transduction drug effects
Antineoplastic Agents therapeutic use
Carcinoma, Squamous Cell drug therapy
Head and Neck Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1744-7658
- Volume :
- 21
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Expert opinion on investigational drugs
- Publication Type :
- Academic Journal
- Accession number :
- 22239178
- Full Text :
- https://doi.org/10.1517/13543784.2012.651455